Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Getting to MRD in ALL boosted survival

Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

Key clinical point: Minimal residual disease (MRD)–negative complete remission was strongly associated with improved survival outcomes.

Major finding: Patients who achieved MRD-negative complete remission had an improved median disease-free survival at 7.6 months versus 0.8 months (P less than .0001)

Study details: A retrospective analysis including 53 patients with ALL who had bone marrow or extramedullary disease at baseline and had received CD19 CAR T cells at or under the maximum tolerated dose at least 1 year prior to this analysis.

Disclosures: Researchers reported financial ties to Juno Therapeutics, Cell Medica, Celgene, Eureka Therapeutics, Genentech/Roche, Gilead Sciences, Kite Pharma, Novartis, and others.

Source: Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

Read the article.

Citation:

Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

This Week's Must Reads

Policy statement on access to opioid medications, Statement on Opioid Use in Patients with Hematologic Diseases and Disorders, American Society of Hematology

FDA approves Mircera for dialysis-related anemia in pediatric patients, FDA approved-drug notice, June 7, 2018; Mircena label (Drugs@FDA)

FDA approves pembrolizumab for relapsed/refractory PMBCL, FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information (Drugs@FDA)

Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.

Red cell tranfusion may increase risk of postsurgical VTE, Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565

Must Reads in ALL (Acute Lymphoblastic Leukemia)

Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

Pediatric cancers rising, Siegel DA et al. ASPHO 2018, Abstract 605.

In T-ALL, methotrexate and nelarabine boosted chemo response, Dunsmore KP et al. ASCO 2018, Abstract 10500.

Fertility poor irrespective of conditioning regimen for transplants , Oquendo del Toro H et al. The 2018 Bone Marrow Transplant Tandem Meetings, Abstract 88.